(Q33815841)

29 July 2017

0 references

1 reference

title

Efficacy of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for prevention of stroke (English)

1 reference

29 July 2017

S Warshafsky

1

1 reference

29 July 2017

D Packard

2

1 reference

29 July 2017

S J Marks

3

1 reference

29 July 2017

N Sachdeva

4

1 reference

29 July 2017

D M Terashita

5

1 reference

29 July 2017

G Kaufman

6

1 reference

29 July 2017

K Sang

7

1 reference

29 July 2017

A J Deluca

8

1 reference

29 July 2017

S J Peterson

9

1 reference

29 July 2017

W H Frishman

10

1 reference

29 July 2017

publication date

1 December 1999

1 reference

Journal of General Internal Medicine

29 July 2017

published in

1 reference

29 July 2017

volume

14

1 reference

29 July 2017

issue

12

1 reference

29 July 2017

page(s)

763-774

1 reference

https://scigraph.springernature.com/pub.10.1046/j.1525-1497.1999.02109.x

29 July 2017

exact match

0 references

cites work

Meta-analysis and quality of evidence in the economic evaluation of drug trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1496862

Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1496862

Cholesterol and coronary heart disease. The 21st century

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1496862

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1496862

Meta-analysis, clinical trials, and transferability of research results into practice. The case of cholesterol-lowering interventions in the secondary prevention of coronary heart disease

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1496862

Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1496862

Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1496862

Design and recruitment in the United States of a multicenter quantitative angiographic trial of pravastatin to limit atherosclerosis in the coronary arteries (PLAC I).

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1496862

Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1496862

Prognostic significance of progression of coronary atherosclerosis

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1496862

Efficacy and tolerability of lovastatin in 3390 women with moderate hypercholesterolemia

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1496862

Relation of coronary heart disease incidence and total mortality to plasma cholesterol reduction in randomised trials: use of meta-analysis

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1496862

Cholesterol reduction and the risk for stroke in men. A meta-analysis of randomized, controlled trials

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1496862

Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1496862

The association between cholesterol and death from injury

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1496862

Assessing possible hazards of reducing serum cholesterol

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1496862

Impact of intensive lipid modulation on angiographically defined coronary disease: clinical implications

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1496862

Coronary artery disease regression. Convincing evidence for the benefit of aggressive lipoprotein management

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1496862

By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1496862

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1496862

An overview of trials of cholesterol lowering and risk of stroke

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1496862

Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1496862

Cholesterol reduction yields clinical benefit. A new look at old data

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1496862

Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1496862

Cholesterol and Recurrent Events: a secondary prevention trial for normolipidemic patients. CARE Investigators.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1496862

The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in Scottish men.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1496862

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1496862

Publication bias: the case for an international registry of clinical trials

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1496862

Quantitative methods in the review of epidemiologic literature

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1496862

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1496862

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1496862

Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1496862

Progression of carotid atherosclerosis and its determinants: a population-based ultrasonography study

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1496862

A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project--1981-86. 2. Incidence, case fatality rates and overall outcome at one year of cerebral infarction, primary intracerebral and subarachnoi

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1496862

Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1496862

Expanded clinical evaluation of lovastatin (EXCEL) study: design and patient characteristics of a double-blind, placebo-controlled study in patients with moderate hypercholesterolemia.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1496862

Lovastatin and simvastatin prevention studies

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1496862

Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH)

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1496862

Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1496862

Simvastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1496862

Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1496862

Problems induced by meta-analyses

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1496862

Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: The cholesterol and recurrent events trial (CARE)

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1496862

Might treatment of hypercholesterolaemia increase non-cardiac mortality?

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1496862

Classification and natural history of clinically identifiable subtypes of cerebral infarction

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1496862

Should there be a moratorium on the use of cholesterol lowering drugs?

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1496862

Report of the Conference on Low Blood Cholesterol: Mortality Associations

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1496862

Meta-analysis: State-of-the-Science

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1496862

Smooth Muscle Cells in the Development of Plasmatic Arterionecrosis, Arteriosclerosis, and Arterial Contraction

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1496862

Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries.

4 July 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.1999.02109.X

Design features of a controlled clinical trial to assess the effect of an HMG CoA reductase inhibitor on the progression of coronary artery disease. Canadian Coronary Atherosclerosis Intervention Trial Investigators Montreal, Ottawa, and Toronto, Ca

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.1999.02109.X

Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.1999.02109.X

Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.1999.02109.X

Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.1999.02109.X

Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.1999.02109.X

Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.1999.02109.X

Survival and recurrence following stroke. The Framingham study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.1999.02109.X

Antiatherothrombotic properties of statins: implications for cardiovascular event reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.1999.02109.X

Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.1999.02109.X

Design features and baseline characteristics of the LIPID (long-term intervention with pravastatin in ischemic disease) study: A randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.1999.02109.X

Design, rationale, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project—A combined analysis of three large-scale randomized trials: Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID), Cholesterol and Re

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.1999.02109.X

The National Survey of Stroke. Incidence.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1496862

Secular trends in stroke incidence and mortality. The Framingham Study

30 October 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.1999.02109.X

Efficacy of Gemfibrozil in Dyslipidaemic Subjects with Suspected Heart Disease. An Ancillary Study in the Helsinki Heart Study Frame Population

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.1999.02109.X

Serum cholesterol and hemorrhagic stroke in the Honolulu Heart Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.1999.02109.X

Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.1999.02109.X

Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II)

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.1999.02109.X

Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.1999.02109.X

Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.1999.02109.X

Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical events

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.1999.02109.X

Prospective meta-analysis of cholesterol-lowering studies: the Prospective Pravastatin Pooling (PPP) Project and the Cholesterol Treatment Trialists (CTT) Collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.1999.02109.X

Pravastatin, lipids, and atherosclerosis in the carotid arteries: design features of a clinical trial with carotid atherosclerosis outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.1999.02109.X

Management of the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study after the Scandinavian Simvastatin Survival Study (4S)

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.1999.02109.X

Prevention of restenosis after coronary balloon angioplasty: rationale and design of the Fluvastatin Angioplasty Restenosis (FLARE) Trial. The FLARE Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.1999.02109.X

Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.1999.02109.X

Effects of intensive lipid-lowering therapy on the coronary arteries of asymptomatic subjects with elevated apolipoprotein B

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.1999.02109.X

Screening experience and baseline characteristics in the West of Scotland Coronary Prevention Study. The WOSCOPS Study Group. West of Scotland Coronary Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.1999.02109.X

Validity of the 4S simvastatin trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.1999.02109.X

Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.1999.02109.X

Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. The Pravastatin Multinational Study Group for Cardiac Risk Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.1999.02109.X

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.1999.02109.X

Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Harvard Atherosclerosis Reversibility Project (HARP) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.1999.02109.X

Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.1999.02109.X

Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter Euro

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.1999.02109.X

Evaluation of the associations between carotid artery atherosclerosis and coronary artery stenosis. A case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.1999.02109.X

Prevention of restenosis by lovastatin after successful coronary angioplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.1999.02109.X

Reduction in coronary events during treatment with pravastatin. PLAC I and PLAC II Investigators. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.1999.02109.X

Cholesterol reduction and its impact on coronary artery disease and total mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.1999.02109.X

Dyslipidemia and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.1999.02109.X

An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.1999.02109.X

Design and baseline results of the Scandinavian Simvastatin Survival Study of patients with stable angina and/or previous myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.1999.02109.X

Pravastatin, lipids, and major coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.1999.02109.X

WHO clofibrate/cholesterol trial: clarifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.1999.02109.X

Spatial distribution of carotid intimal-medial thickness as measured by B-mode ultrasonography

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.1999.02109.X

A coronary primary prevention study of Scottish men aged 45-64 years: trial design. The West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.1999.02109.X

Associations of serum total cholesterol, different types of stroke, and stenosis distribution of cerebral arteries. The Akita Pathology Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.1999.02109.X

Ethnic differences in stroke mortality between non-Hispanic whites, Hispanic whites, and blacks. The National Longitudinal Mortality Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.1999.02109.X

Reductase inhibitor monotherapy and stroke prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.1999.02109.X

Effect of HMGcoA reductase inhibitors on stroke. A meta-analysis of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.1999.02109.X

Rationale and design for the Asymptomatic Carotid Artery Plaque Study (ACAPS). The ACAPS Group

21 January 2018

1 reference

12 December 2020

Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS)

1 reference

12 December 2020

The successful recruitment of elderly black subjects in a clinical trial: the CRISP experience. Cholesterol Reduction in Seniors Program

1 reference

12 December 2020

Profiling a landmark clinical trial: Scandinavian Simvastatin Survival Study

1 reference

12 December 2020

Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a)

1 reference

12 December 2020

10.1046/J.1525-1497.1999.02109.X

Identifiers

DOI

1 reference

Dimensions Publication ID

29 July 2017

0 references

1 reference

29 July 2017

1 reference